Welcome to our dedicated page for Lftd Partners SEC filings (Ticker: LIFD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the revenue impact of new hemp regulations, the latest vape cartridge acquisition, or evidence of executive stock sales? The LFTD Partners SEC filings explained simply page guides you straight to the numbers that drive this niche cannabinoid business.
Start with the LFTD Partners annual report 10-K simplified to see how changes in federal and state laws could reshape margins, then pivot to each LFTD Partners quarterly earnings report 10-Q filing for real-time sales trends across gummies, vapes, and other psychoactive products. Our AI highlights risk factor updates, reconciles segment data, and flags covenant disclosures—so you spend minutes, not hours, parsing footnotes.
Need event-driven insights? Every LFTD Partners 8-K material events explained post lands here seconds after EDGAR acceptance, while LFTD Partners Form 4 insider transactions real-time show when leadership buys or sells shares ahead of product launches. Stock Titan’s AI summarizes each LFTD Partners insider trading Form 4 transactions entry, translating technical tables into clear narratives you can act on.
- Track LFTD Partners executive stock transactions Form 4 to monitor confidence levels
- Dive into LFTD Partners earnings report filing analysis for margin drivers
- Compare pay packages with the latest LFTD Partners proxy statement executive compensation
- Save time by understanding LFTD Partners SEC documents with AI summaries and red-flag alerts
From comprehensive coverage of every form type to plain-English AI commentary, this page transforms dense disclosures into practical intelligence for cannabinoid-sector investors.
LFTD Partners (LIFD) reported a profitable Q3 2025, with net sales of $9,056,742 and net income of $634,257, reversing a loss a year ago. Gross profit rose to $4,157,495 on lower operating expenses, lifting income from operations to $1,312,791.
For the nine months, net sales were $28,505,928 and net income was $62,265. Cash and cash equivalents were $1,920,664, with restricted cash of $1,000,000. The company reduced Surety Bank borrowings during Q3, including a $592,050 paydown on its working capital loan. Shares outstanding were 14,822,678 as of November 13, 2025.
Risks increased materially. On November 12, 2025, a federal act was signed that bans intoxicating hemp-derived consumable products nationally on November 12, 2026. Hemp-derived products accounted for approximately 47% of Q3 sales. Management warns the act could trigger goodwill impairments on total goodwill of $23,092,794, potential impairment of a $399,200 investment, and significant inventory write-offs. The company states there is substantial doubt about its ability to continue as a going concern.
FAQ
What is the current stock price of Lftd Partners (LIFD)?
What is the market cap of Lftd Partners (LIFD)?
